Coherus Biosciences | CHRS - Operating Profit


Coherus Biosciences reported $-39.08M in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
AbbVie USD 6.88B 156M Sep/2026
Acadia Pharmaceuticals USD 71.72M 33.88M Sep/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
ALKERMES USD 36.59M 102.52M Sep/2026
Alnylam Pharmaceuticals USD 179.66M 67.06M Sep/2026
Amarin USD -2.26M 564K Dec/2025
Amgen USD 4.68B 65M Sep/2026
Baxter International USD 314M 38M Sep/2026
Biogen USD 419.5M 663.3M Sep/2026
BioMarin Pharmaceutical USD 205.6M 100M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Coherus Biosciences USD -39.08M 3.65M Dec/2025
Eli Lilly USD 12.46B 2.68B Jun/2026
Fujifilm JPY 101.76B 11.79B Mar/2026
Gilead Sciences USD 3.85B 1.17B Jun/2026
Ironwood Pharmaceuticals USD 33.22M 7.58M Dec/2024
Merck USD 7.33B 6.49B Sep/2026
Myriad Genetics USD -3M 20.3M Dec/2025
Pacira USD 2.57B 2.56B Sep/2026
Perrigo USD 27.2M 3.7M Sep/2026
Pfizer USD 662M 5M Sep/2026
PTC Therapeutics USD 148.98M 103.09M Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Sarepta Therapeutics USD 13.29M 345.14M Jun/2026
Teva Pharmaceutical Industries USD 1.19B 954M Sep/2026
Vertex Pharmaceuticals USD 1.26B 11.3M Sep/2026
Xencor USD -36.6M 41.26M Jun/2026
Zoetis USD 1.03B 88M Sep/2026